For thousands in Portugal, a simple handshake or wearing a favorite wool sweater is an unthinkable source of agony.
Imagine your skin screaming with itch so intense that sleep becomes a distant memory. Your concentration shatters, social gatherings turn into anxiety-filled trials, and the simple act of a handshake becomes a source of shame. This isn't a scene from a medical drama—it's the daily reality for many Portuguese patients living with atopic dermatitis (AD), a chronic inflammatory skin condition that reaches far deeper than the surface 1 .
Recent research from Portugal reveals a healthcare landscape where patients navigate years of diagnostic delays, undertreatment, and profound impacts on their mental health and quality of life, all while the healthcare system grapples with modernization and the lingering effects of a global pandemic 1 5 .
This article delves into the scientific journey to quantify this hidden suffering, exploring the crucial experiments uncovering the true burden on Portuguese patients and the emerging pathways toward more humane, person-centered care.
Many people dismiss eczema as just a "skin rash," but science tells a far more complex story. Atopic dermatitis is a Th-2 mediated inflammatory disease, characterized by a malfunctioning immune system and a severely compromised skin barrier. This isn't merely a cosmetic issue; it's a systemic condition that leaves patients vulnerable to infections, allergies, and a myriad of other health complications 1 .
On average, patients experience a two-year gap between their first symptoms and receiving an official diagnosis, a critical period during which the disease can progress and significantly impact their lives 1 .
To truly understand the Portuguese AD experience, researchers conducted an observational study from June 2019 to January 2020, putting patients' voices at the center of the investigation 1 .
The study was built on a simple but powerful premise: ask the patients. Two hundred and four individuals with a confirmed AD diagnosis from a specialist completed a detailed, 70-question questionnaire. This wasn't a simple survey; it incorporated validated scientific metrics to ensure robustness:
Patients Participated
Questions in Survey
Study Duration
The researchers collaborated with ADERMAP, the national association for atopic dermatitis, to reach participants, ensuring the study captured a wide spectrum of experiences. The data was then rigorously analyzed, with statistical checks to control for potential biases and ensure the findings were representative 1 .
The 204 respondents painted a clear demographic picture. The average participant was 31.1 years old, and the majority (64%) were female, a gender distribution consistent with global AD patterns. These were not newly diagnosed patients; on average, they had lived with the disease for 15 years, with over a third suffering for more than two decades. This long-term perspective was crucial for understanding the chronic, lifelong burden of the condition 1 .
When researchers analyzed the responses, a clear and concerning narrative emerged, quantified in the following data visualizations.
The data revealed that the impact of AD is severe and directly linked to disease severity. Patients reported high levels of suffering and a significantly reduced quality of life 1 .
The DLQI scores are particularly telling. A score above 10 indicates a very large effect on a patient's life, which was the case for those with moderate to severe disease. The distribution of lesions also widened with severity, with sensitive areas like the face, abdomen, and feet becoming more commonly affected in severe cases, adding to the patient's daily distress 1 .
The study uncovered significant hurdles in the patient's journey to managing their disease, including delayed diagnoses and a puzzling disconnect between treatment guidelines and real-world practice 1 .
This "treatment paradox" is stark. Despite questionable effectiveness for AD, almost all severe patients were prescribed antihistamines, while a much smaller fraction had access to modern biological drugs that target the specific inflammation pathways of the disease. This points to a significant gap in access to innovative therapies for Portuguese patients 1 .
What does it take to translate human suffering into hard data? Researchers rely on a specific toolkit of validated instruments and reagents to ensure their findings are accurate and meaningful.
Function: A 10-question questionnaire that measures how much a skin disease affects a patient's quality of life over the previous week.
Why It Matters: It turns subjective experiences like embarrassment or sleep loss into a quantifiable score, allowing for comparison and tracking over time.
Function: A scale from 0-100 where patients self-rate their overall health state, with 100 being "the best health you can imagine."
Why It Matters: Provides a direct, global measure of a patient's perceived health, capturing the cumulative burden of their condition.
The story of atopic dermatitis in Portugal is a microcosm of broader challenges and evolutions within the Portuguese healthcare system.
The COVID-19 pandemic placed unprecedented strain on the system, exacerbating existing issues. During the pandemic, more than a quarter of Portuguese citizens had medical appointments or exams postponed or canceled. This led to a documented decline in mental well-being, with about half of the respondents in a 2021 survey reporting feeling nervous, anxious, or on edge, and 29% experiencing loneliness 5 . For chronic disease patients already navigating a complex system, these disruptions created additional layers of stress and delayed care.
Simultaneously, a powerful shift toward person-centered practice (PCP) is underway. The Portuguese National Health Service has launched initiatives like 'SNS + Proximity' to place the citizen at the center of care. This philosophy emphasizes the importance of understanding the patient's narrative, building partnerships, and respecting individual preferences and needs 8 . This is not just an abstract ideal; it is being operationalized through the validation of tools like the Quality of Oncology Nursing Care Scale (QONCS_PT), which allows cancer patients to evaluate the holistic, respectful care they receive from nurses .
Limited focus on patient-reported outcomes and experiences in chronic disease management.
Landmark AD study highlights diagnostic delays and treatment gaps, putting patient experiences at the forefront.
COVID-19 pandemic exacerbates healthcare challenges but also accelerates digital health adoption.
Increased focus on person-centered care initiatives and validation of patient experience measurement tools.
The journey into the lives of Portuguese patients, particularly those with chronic conditions like atopic dermatitis, reveals a landscape marked by resilience in the face of significant challenge. The scientific evidence is clear: the burden is real, multidimensional, and for too long, has been underappreciated. Diagnostic delays and potential undertreatment signify systemic hurdles that need addressing 1 .
Yet, the same science that quantified this burden also lights the path forward. By listening to patient narratives and rigorously measuring their experiences, Portugal is building the foundation for a more responsive, person-centered healthcare system. The increased focus on patient-reported outcomes and experiences, the push for person-centered care standards, and the continued research into the real-world patient journey are all reasons for optimism 8 .
For the thousands of Portuguese patients living with atopic dermatitis and other chronic conditions, this research is more than just data—it is validation of their struggle and a crucial step toward a future where their suffering is not only seen but effectively alleviated. The message from the science is clear: when we look beyond the surface, we can begin to heal what lies beneath.
Average Diagnostic Delay
Average Disease Duration
Female Patients
Prescribed Antihistamines